Skip to main content

Table 1 Base-line characteristics

From: Patients with Type 2 Diabetes Mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin

 

Placebo

Vildagliptin

N

6

9

Age (years)

60 (39–67)

64 (42–67)

BMI (kg/m2)

32 (26–35)

32 (27–34)

Female (%)

17%

22%

Duration DM (years)

5.5 (1–23)

6.0 (2–15)

Prior medication

  

metformin/SU/TZD/other (%)

100/67/0/33%

100/89/11/22%

Diabetic complications

  

any microvascular complication (%)

17%

33%

any macrovascular complication (%)

0%

33%

BP (syst/diast in mmHg)

128/78

126/73

HbA1c at start of the trial (mmol/mol)

64 (53–74)

62 (57–73)

(%)

8.0 (7.0-8.9)

7.8 (7.4-8.8)

SD of glucose values (variability) at start of trial

1.8 (1.0 -2.7)

1.7 (1.2 – 2.6)

  1. All values are in median (range) or percentages.
  2. Any micro- or macrovascular complication was defined as the percentage of patients who had one or more complications as judged clinically by the investigator at the moment of inclusion.
  3. Abbreviations: BMI = body mass index, DM = diabetes mellitus, SU = sulfonylurea, TZD = thiazolidinediones, BP = blood pressure, HbA1c = glycated haemoglobin, SD = standard deviation.